Biomedical Occupation or Discipline – Page 12 – Talk Bio

Actionable Insights Powered by AI

Newleos Therapeutics Launches with $93.5M to Advance Novel Neuropsychiatric Treatments

6 months ago talkbio0Tagged Anxiety Disorders, assets, Funding, GABA Modulators, mental health, Neuropsychiatry, Newleos, Roche (company), Series, Substance Use Disorders

Newleos Therapeutics, mental health, neuropsychiatry, Roche assets, Series A funding, anxiety disorders, substance use disorders, GABA modulators

Newleos Therapeutics Launches with $93.5M to Develop Novel Neuropsychiatric Treatments

6 months ago talkbio0Tagged Anxiety Disorders, Clinical Trials, GABA A, Longwood Fund, Neuropsychiatry, Newleos, Roche (company), Substance Use Disorders

Newleos Therapeutics, Longwood Fund, neuropsychiatry, anxiety disorders, substance use disorders, Roche, GABA A -γ1, clinical trials

Axplora Invests €50M in GLP-1 Manufacturing Expansion at Mourenx, France

6 months ago talkbio0Tagged alpha 1-antitrypsin, Axplora, biology (field), CDMO, Chromatography, Diabetes, expansion, France, Glucagon-Like Peptide 1, Manufacturing, Mourenx, Obesity, production

Axplora, GLP-1, manufacturing expansion, Mourenx, France, CDMO, API production, chromatography, diabetes, obesity, biologic therapies

AnaptysBio’s Rosnilimab Shows Promising Results in Phase 2b Rheumatoid Arthritis Trial, Driving Stock Surge

6 months ago talkbio0Tagged AnaptysBio, Immunology, Increase, Prices, RENOIR, Rheumatoid Arthritis, Rosnilimab, Treatment Effectiveness

AnaptysBio, rosnilimab, rheumatoid arthritis, Phase 2b trial, RENOIR study, clinical efficacy, stock price increase, immunology therapeutics

AbbVie and Xilio Therapeutics Forge $2.1 Billion Partnership for Novel Tumor-Activated Immunotherapies

6 months ago talkbio0Tagged AbbVie, Collaboration, Drug Development, engagers, Immunotherapy, Neoplasms, T-Lymphocyte, tumor-activated

AbbVie, Xilio Therapeutics, immunotherapy, tumor-activated, T cell engagers, collaboration, oncology, drug development

Voyager Therapeutics Halts ALS Gene Therapy Development Due to Off-Target Effects

6 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Capsid, Cu-Zn Superoxide Dismutase, Drug Development, Effect, gene therapy, off-target, payload, Preclinical, RNA, Small Interfering, Tracer, VY9323

SOD1 ALS gene therapy, Off-target effects, VY9323, siRNA payload, TRACER capsid, Preclinical data, Drug development delay

Roivant’s Kinevant Discontinues Namilumab Development for Pulmonary Sarcoidosis After Phase 2 Failure

6 months ago talkbio0Tagged Drug Development, Failure (biologic function), Kinevant, namilumab, Phase 2 clinical trial, Roivant, Sarcoidosis, Pulmonary

Roivant Sciences, Kinevant, namilumab, pulmonary sarcoidosis, Phase 2 clinical trial, RESOLVE-Lung study, drug development failure

J&J’s Swift $14.6B Acquisition of Intra-Cellular Therapies: A CEO-Driven Deal

7 months ago talkbio0Tagged Acquisition, Caplyta, Drug Industry, Duato, Intra-Cellular Therapies, Joaquin, Johnson and Johnson, M&A, Neuroscience discipline

Johnson & Johnson, Intra-Cellular Therapies, acquisition, neuroscience, CAPLYTA, Joaquin Duato, pharmaceutical industry, M&A

Eli Lilly Streamlines Pipeline, Removing Alzheimer’s and Obesity Candidates in Q4 2024

7 months ago talkbio0Tagged Alzheimer 's disease, Ceperognastat, Clinical Trials, Drug Development, Eli, Eli Lilly, Obesity, pipeline update

Eli Lilly, pipeline update, Alzheimer’s disease, obesity, ceperognastat, clinical trials, drug development

Boston Scientific’s Farapulse PFA System Surpasses $1 Billion in Revenue, Transforming Electrophysiology Market

7 months ago talkbio0Tagged Atrial Fibrillation, Boston Scientific, Electrophysiology (science), Farapulse, field ablation, innovation, Medical Devices, Revenue Milestone

Boston Scientific, Farapulse, pulsed field ablation, atrial fibrillation, electrophysiology, revenue milestone, medical device innovation